Posts Archive

NCT05137054: Phase 1: REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) Plus Other Cancer Treatments for Participants With...

NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma...

Pavurutamab NCT04998747: Phase 1: A Study of Subcutaneous (SC) AMG 701 in Participants With Relapsed or Refractory Multiple Myeloma...

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma...

NCT04975399: Phase 1: Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple...

NCT04960579: Phase 1: P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma (MM) NCT04960579: Phase 1:...

NCT04754945: Phase 1: Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis NCT04754945: Phase 1: Isatuximab as...

MAGNETISMM-2 NCT04798586: Phase 1: MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma...

NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma Newly Diagnosed Multiple Myeloma...

Phase 1 Relapsed & Refractory Myeloma A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma The...

NCT04855929: Phase 1: A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer and Multiple Myeloma....

NCT04688853: Phase 1 - A Study to Investigate the Safety and Efficacy of TEG002 in Relapsed/Refractory Multiple Myeloma Patients This is...

A Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma This is a Phase 1, multicenter, open label, study of...

NCT04570631: Phase 1: Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or...

NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies COM902 (A TIGIT Inhibitor) in Subjects With...

NCT04634435: Phase 1/2: Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma...

MCARH109 CART MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma This study will test the...

UNIVERSAL Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma...

NCT04405167: Phase 1: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma NCT04405167: Phase 1: Tasquinimod for the Treatment...